{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PROC",
    "query": {
      "condition": "PROC"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PROC&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T20:23:06.764Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07470853",
      "title": "A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PROC",
        "Platinum Resistant Ovarian Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "HWK-016, MUCIN-16-targeted ADC",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Whitehawk Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 265,
      "start_date": "2026-03-15",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 12,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sarasota, Florida + 9 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07470853"
    },
    {
      "nct_id": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Soft Tissue Sarcoma (STS)",
        "Platinum-resistant Ovarian Cancer (PROC)",
        "Hepatocellular Carcinoma (HCC)",
        "Colorectal Cancer (CRC)",
        "HER2 Negative Breast Cancer",
        "Cutaneous Melanoma",
        "Renal Cell Carcinoma (RCC)"
      ],
      "interventions": [
        {
          "name": "GI-102 subcutaneous (SC)",
          "type": "DRUG"
        },
        {
          "name": "GI-102",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "eribulin",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab deruxtecan (T-DXd)",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GI Innovation, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 358,
      "start_date": "2023-05-30",
      "completion_date": "2027-04-24",
      "has_results": false,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05824975"
    },
    {
      "nct_id": "NCT05243524",
      "title": "Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum-resistant Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Maveropepimut-S",
          "type": "OTHER"
        },
        {
          "name": "Cyclophosphamide 50mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2022-08-05",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Ocala, Florida • Mineola, New York + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05243524"
    },
    {
      "nct_id": "NCT05613088",
      "title": "A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Ovarian"
      ],
      "interventions": [
        {
          "name": "MORAb-202",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin (PLD)",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 106,
      "start_date": "2023-02-01",
      "completion_date": "2025-09-10",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 10,
      "location_summary": "Sacramento, California • San Francisco, California • Whittier, California + 7 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05613088"
    },
    {
      "nct_id": "NCT00386425",
      "title": "Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Sepsis"
      ],
      "interventions": [
        {
          "name": "Drotrecogin alfa (activated)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 486,
      "start_date": "2006-11",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2010-12-16",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00386425"
    },
    {
      "nct_id": "NCT01127529",
      "title": "Ceprotin Treatment Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Protein C Deficiency"
      ],
      "interventions": [
        {
          "name": "Protein C Concentrate (Human)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 43,
      "start_date": "2010-06-23",
      "completion_date": "2015-06-22",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Orange, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01127529"
    },
    {
      "nct_id": "NCT01991210",
      "title": "A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "DNIB0600A",
          "type": "DRUG"
        },
        {
          "name": "PLD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 95,
      "start_date": "2014-02-06",
      "completion_date": "2016-08-17",
      "has_results": false,
      "last_update_posted_date": "2017-08-21",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01991210"
    },
    {
      "nct_id": "NCT06619236",
      "title": "Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Rina-S",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 530,
      "start_date": "2025-02-07",
      "completion_date": "2028-05-23",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 72,
      "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06619236"
    },
    {
      "nct_id": "NCT00533546",
      "title": "Activated Protein C in Acute Stroke Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Activated Protein C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-09",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2016-10-24",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 9,
      "location_summary": "Orange, California • Maywood, Illinois • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00533546"
    },
    {
      "nct_id": "NCT00157118",
      "title": "Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Protein C Deficiency"
      ],
      "interventions": [
        {
          "name": "Protein C Concentrate (Human) Vapor Heated",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 18,
      "start_date": "2003-08-22",
      "completion_date": "2005-03-17",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-06-10T20:23:06.764Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00157118"
    }
  ]
}